Patient-reported outcomes after immediate and delayed DIEP-flap breast reconstruction in the setting of post-mastectomy radiation therapy-results of the multicenter UMBRELLA breast cancer cohort.

IF 3 3区 医学 Q2 ONCOLOGY Breast Cancer Research and Treatment Pub Date : 2025-04-01 Epub Date: 2025-02-03 DOI:10.1007/s10549-025-07613-w
Britt A M Jansen, Claudia A Bargon, Maria A Bouman, Dieuwke R Mink van der Molen, Emily L Postma, Femke van der Leij, Erik Zonnevylle, Quinten Ruhe, Sven E Bruekers, Wiesje Maarse, Sabine Siesling, Danny A Young-Afat, Annemiek Doeksen, Helena M Verkooijen
{"title":"Patient-reported outcomes after immediate and delayed DIEP-flap breast reconstruction in the setting of post-mastectomy radiation therapy-results of the multicenter UMBRELLA breast cancer cohort.","authors":"Britt A M Jansen, Claudia A Bargon, Maria A Bouman, Dieuwke R Mink van der Molen, Emily L Postma, Femke van der Leij, Erik Zonnevylle, Quinten Ruhe, Sven E Bruekers, Wiesje Maarse, Sabine Siesling, Danny A Young-Afat, Annemiek Doeksen, Helena M Verkooijen","doi":"10.1007/s10549-025-07613-w","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Timing of Deep Inferior Epigastric artery Perforator (DIEP)-flap breast reconstruction in the context of post-mastectomy radiotherapy for breast cancer patients is topic of debate. We compared the impact of immediate (before radiotherapy) versus delayed (after radiotherapy) DIEP-flap breast reconstruction (IBR versus DBR) on short- and long-term patient-reported outcomes (PROs).</p><p><strong>Methods: </strong>Within the prospective, multicenter breast cancer cohort (UMBRELLA), we identified 88 women who underwent immediate or delayed DIEP-flap breast reconstruction and received PMRT. At 6 and 12 months post-mastectomy, as well as on long-term (≥ 12 months post-reconstruction) body image, breast symptoms, physical functioning, and pain were measured by EORTC-QLQ-30/BR23. Additionally, long-term evaluation included satisfaction with breast(s), physical well-being and self-reported adverse effects of radiation as measured by BREAST-Q, and late treatment toxicity. PROs were compared between groups using independent sample T-test.</p><p><strong>Results: </strong>IBR was performed in 56 patients (64%) and DBR in 32 patients (36%), with 15 months of median time to reconstruction. At 6 and 12 months post-mastectomy, better body image and physical functioning were observed after IBR. No statistically nor clinically relevant differences were observed in long-term EORTC and BREAST-Q outcomes (median follow-up 37-41 months for IBR vs. 42-46 months for DBR). Patients with IBR reported more fibrosis and movement restriction (median follow-up 29 vs. 61 months, resp.).</p><p><strong>Conclusion: </strong>Long-term PROs were comparable for patients with IBR and DBR, despite more patient-reported fibrosis and movement restriction after IBR. Therefore, both treatment pathways can be considered when opting for autologous breast reconstruction in the setting of PMRT.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":"759-769"},"PeriodicalIF":3.0000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11953195/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Breast Cancer Research and Treatment","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10549-025-07613-w","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/3 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: Timing of Deep Inferior Epigastric artery Perforator (DIEP)-flap breast reconstruction in the context of post-mastectomy radiotherapy for breast cancer patients is topic of debate. We compared the impact of immediate (before radiotherapy) versus delayed (after radiotherapy) DIEP-flap breast reconstruction (IBR versus DBR) on short- and long-term patient-reported outcomes (PROs).

Methods: Within the prospective, multicenter breast cancer cohort (UMBRELLA), we identified 88 women who underwent immediate or delayed DIEP-flap breast reconstruction and received PMRT. At 6 and 12 months post-mastectomy, as well as on long-term (≥ 12 months post-reconstruction) body image, breast symptoms, physical functioning, and pain were measured by EORTC-QLQ-30/BR23. Additionally, long-term evaluation included satisfaction with breast(s), physical well-being and self-reported adverse effects of radiation as measured by BREAST-Q, and late treatment toxicity. PROs were compared between groups using independent sample T-test.

Results: IBR was performed in 56 patients (64%) and DBR in 32 patients (36%), with 15 months of median time to reconstruction. At 6 and 12 months post-mastectomy, better body image and physical functioning were observed after IBR. No statistically nor clinically relevant differences were observed in long-term EORTC and BREAST-Q outcomes (median follow-up 37-41 months for IBR vs. 42-46 months for DBR). Patients with IBR reported more fibrosis and movement restriction (median follow-up 29 vs. 61 months, resp.).

Conclusion: Long-term PROs were comparable for patients with IBR and DBR, despite more patient-reported fibrosis and movement restriction after IBR. Therefore, both treatment pathways can be considered when opting for autologous breast reconstruction in the setting of PMRT.

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
患者报告的乳房切除术后放疗后立即和延迟diep -皮瓣乳房重建的结果-多中心UMBRELLA乳腺癌队列的结果
目的:在乳腺癌患者乳房切除术后放疗的背景下,腹下深动脉穿支(DIEP)皮瓣乳房重建的时机是争论的话题。我们比较了即时(放疗前)与延迟(放疗后)DIEP-flap乳房重建(IBR与DBR)对短期和长期患者报告结果(PROs)的影响。方法:在前瞻性多中心乳腺癌队列(UMBRELLA)中,我们确定了88名接受立即或延迟DIEP-flap乳房重建术并接受PMRT的女性。在乳房切除术后6个月和12个月,以及长期(重建后≥12个月)身体形象、乳房症状、身体功能和疼痛通过EORTC-QLQ-30/BR23进行测量。此外,长期评估包括乳房满意度,身体健康和自我报告的辐射不良反应(由breast - q测量),以及晚期治疗毒性。各组间PROs比较采用独立样本t检验。结果:56例患者(64%)行IBR, 32例患者(36%)行DBR,中位重建时间为15个月。在乳房切除术后6个月和12个月,IBR后的身体形象和身体功能都有所改善。长期EORTC和BREAST-Q结果无统计学和临床相关差异(IBR中位随访37-41个月,DBR中位随访42-46个月)。IBR患者报告更多的纤维化和活动受限(中位随访29个月vs. 61个月)。结论:IBR和DBR患者的长期疗效相当,尽管IBR后患者报告的纤维化和活动受限更多。因此,在PMRT下选择自体乳房重建术时,可以考虑两种治疗途径。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
6.80
自引率
2.60%
发文量
342
审稿时长
1 months
期刊介绍: Breast Cancer Research and Treatment provides the surgeon, radiotherapist, medical oncologist, endocrinologist, epidemiologist, immunologist or cell biologist investigating problems in breast cancer a single forum for communication. The journal creates a "market place" for breast cancer topics which cuts across all the usual lines of disciplines, providing a site for presenting pertinent investigations, and for discussing critical questions relevant to the entire field. It seeks to develop a new focus and new perspectives for all those concerned with breast cancer.
期刊最新文献
Neoadjuvant twelve weekly paclitaxel-carboplatin with trastuzumab and pertuzumab in HER2-positive breast cancer. The LIFT UP study: feasibility of systematically identifying and addressing resource needs in those with metastatic breast cancer. Kidney function changes associated with trastuzumab use in women with breast cancer: a retrospective cohort study. Alpelisib and Fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the German PRAEGNANT trial. Utilizing natural language processing (NLP) to identify breast cancer-associated lung metastases from pathology reports to delineate characteristics of this site of recurrence.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1